

article du 21 avril 2021

[nature.com](https://www.nature.com)

# CBD, a precursor of THC in e-cigarettes

Dezső Csupor  
28-35 minutes

## Abstract

The use of cannabidiol (CBD) in electronic cigarettes is widespread. Previously, it was reported that CBD is partly transformed to THC in case smoking as a cigarette, however, the pyrolysis of this compound has not been assessed extensively. The aim of our study was to investigate the effect of temperature on the composition of pyrolysis products of CBD. The experiments were performed in the typical operating temperature range of e-cigarettes (250–400 °C) and at 500 °C under both inert and oxidative conditions, and the pyrolysis products were identified and quantified by GC–MS. Depending on the temperature and atmosphere, 25–52% of CBD was transformed into other chemical substances:  $\Delta^9$ -THC,  $\Delta^8$ -THC, cannabinol and cannabichromene were the predominant pyrolysates in both conditions, all formed by cyclization reaction. THC was the main pyrolysis product at all temperatures under both oxidative and inert conditions. Our results point out that CBD in e-cigarettes can be considered as a precursor of THC, thus it bears all the dangers related to this psychoactive compound. Our findings are fundamental contributions to the safety profile of CBD-based e-cigarettes.

## Introduction

In recent years, the consumption of *Cannabis sativa*-based products has been on the rise. The main bioactive compounds of the plant are phytocannabinoids, more than 110 of which have been identified so far<sup>1</sup>. (–)-*trans*- $\Delta^9$ -Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the major substances of *Cannabis*, the former known for its psychoactivity. Due to the widespread use of the plant for recreational purposes, plant breeding aimed at production of plant material rich in THC for decades. Nowadays, it seems like that the focus has been shifted from THC to CBD, since there is a growing demand from the food supplement industry for THC-free extracts with CBD as the major constituent. Cannabidiol (CBD) is a non-psychoactive compound possessing several supposed and proved beneficial health effects.

In the US, a record-breaking increase in CBD sales was generated in the past 2 years. In general, oils, tinctures, soft gels as well as liquids are found to be the most widely used forms for CBD preparations. Approximately one fifth of the US population have used some type of CBD related products in recent years<sup>2</sup>. Flowers, leaves, seeds from the cannabis plant are known to have traditionally been used as anti-inflammatory, pain relieving, antidepressant, and anticonvulsant remedies<sup>3</sup>. Authorities both in the EU and USA have lately approved the CBD-containing medicine Epidiolex® for treating children of age two or older with severe epileptic seizures. However, the current rise of *Cannabis* is only partly related to the

medicinal use of CBD. Most of the CBD-containing products are marketed as food supplements.

Besides medical and food use, other CBD formulations, including liquids for electronic cigarettes, have also emerged. The popularity of these liquids is increasing. In the Washington State area, cannabis extracts used for inhalation possessed 21.2% of the purchases, which was almost one and a half times higher in 2016 than it was in 2014<sup>4</sup>. Despite the safety claims of e-cigarettes, in some cases the appearance of lung injuries by vaping e-liquids containing CBD as an additive were reported. The possibly harmful pyrolysis products could have toxic effects in the human body<sup>5</sup>. Moreover, the evaporated CBD itself might increase the risk of cardiovascular events<sup>6</sup>.

Lawfully produced CBD products are available in the European Union but not all member states allow the distribution of them. In a French court decision, company directors from the Czech Republic were sentenced to suspended imprisonment for marketing electronic cigarette cartridges in France. Legislative authorities in France could prohibit the marketing of *Cannabis sativa* extracts based on the narcotic hallmark of CBD, thus labeling distributors as criminals<sup>7</sup>, even though CBD itself is not psychoactive and is not reckoned as a controlled substance by the UN Commission on Narcotic Drugs.

Smoking or using e-cigarette exposes compounds to temperatures sufficient to promote chemical reactions, modifying the composition of the smoke this way. It has been reported even in the 1970's that CBD is partly transformed to THC in case smoking as a cigarette<sup>8</sup>. This was reassured later in pyrolysis studies performed at 700 °C<sup>9</sup> or under simulated smoking conditions<sup>10</sup>, however, this pyrolysis reaction has not been studied extensively. The widespread use of CBD in e-cigarettes necessitates quantitative data on the pyrolytic transformation of CBD at lower pyrolysis temperatures. The aim of our research work presented here was to analyze the pyrolysis products of CBD by adopting standard heating conditions used in electronic cigarettes<sup>11,12</sup>, with special focus on THC.

## Results

Depending on e-liquid fill level, coil resistance and voltage settings, the coil temperatures of e-cigarettes ranges from 110 to 1008 °C<sup>11,13</sup>. Typical wetted coil temperature is 200–400 °C, extremely high temperatures (around 1000 °C) have been measured for dry coils without any e-liquid<sup>14</sup>. In our experiments, we studied pyrolysis in the typical operating temperature range of e-cigarettes (250–400 °C) under both inert and oxidative conditions. Additional experiments were performed at 500 °C in both atmospheres to test thermal degradation pattern at elevated temperatures.

The composition of CBD pyrolysates obtained in inert and oxidative atmospheres are summarized in Tables [1](#) and [2](#), respectively. The obtained data clearly present the thermal instability of CBD. Depending on the temperature and atmosphere, 25–52% of CBD transformed into other chemical substances during the experiments. In the absence of oxygen, 23 pyrolysis products were observed, 15 of which were identified (see Table [1](#)). These compounds represented 81–97% of the pyrolysis products (at lower temperatures, between 250–400 °C, 93–97%). In the presence of oxygen, 22 pyrolysis products were detected (see Table [2](#)), the identified 15 components represent the 88–96% of the degradation products in the studied temperature range. Most of the degradation products (i.e. 18 compounds)

appeared among both inert and oxidative conditions. Additional four products were observed exclusively in oxidative, while five degradation products exclusively in inert atmosphere.

**Table 1 Product distribution of CBD at various temperatures in inert atmosphere.**

[Full size table](#)

**Table 2 Product distribution of CBD at various temperatures in oxidative atmosphere.**

[Full size table](#)

The four most intense products, namely  $\Delta^9$ -THC,  $\Delta^8$ -THC, cannabichromene and cannabinol account for more than 95% of the decomposition products at 250 and 300 °C pyrolysis temperatures in inert atmosphere. Under oxidative conditions an additional product, cannabielsoin appeared. The ratio of the aforementioned five decomposition products is more than 80% under oxidative conditions up to 300 °C. All of these compounds formed by cyclization reaction (see Fig. 1). Cyclization of phenolic flavors to bicyclic compounds under simulated tobacco heating conditions at 300 °C was reported earlier<sup>15</sup>. The phenolic O of thymol or ethylvanillin link to a geometrically favorable position of a sterically adjacent side group of the molecule, forming a bicyclic compound. Analogously, in the present case one of the phenolic O of CBD linked to the tertiary carbon of the isopropenyl group, thus forming a sterically favored six-membered ring and resulting  $\Delta^9$ -THC molecule. However,  $\Delta^9$ -THC formed also under inert atmosphere. The related cyclization can be formally described as an intramolecular Markovnikov addition of the phenolic OH onto the double bond of the isopropenyl group. Thus, no oxidation step is needed by the formation of  $\Delta^9$ -THC. The psychoactive  $\Delta^9$ -THC was the main detected compound, accounting up to 42% and 70% of the decomposition products under oxidative and inert conditions, respectively, at all applied temperatures. One possible reason of the lower  $\Delta^9$ -THC amount in oxidative atmosphere measured in our study could be the higher decomposition rate of the formed  $\Delta^9$ -THC in the oxidative ambient. Increased degradation rate of  $\Delta^9$ -THC was published in cannabis resin sample exposed to air comparing to that of stored in a sealed plastic bag at ambient temperature<sup>16</sup> indicating the role of oxygen in  $\Delta^9$ -THC decomposition.

**Figure 1**

The major thermal decomposition routes of CBD in inert (helium) and oxidative (9% oxygen in nitrogen) atmosphere in a temperature range of 250–500 °C.

[Full size image](#)

Among THC isomers,  $\Delta^8$ -THC has also psychotropic effects according to the recent review of the Expert Committee on Drug Dependence of the World Health Organization (WHO)<sup>17</sup>. The  $\Delta^8$ -THC molecule formed by an additional isomerization to the cyclization during thermal treatment. Both  $\Delta^9$ -THC and  $\Delta^8$ -THC were formed at higher rate in inert atmosphere and at relative lower temperatures (250–300 °C). By increasing the temperature, the relative yield of THC decreased, while other decomposition reactions became more pronounced.

According to earlier studies, cannabinol derives by cyclization, dehydration, and aromatization of CBD, probably through a THC intermediate during long-term storage<sup>16</sup>. Notable amount of cannabinol was detected in the present study as a thermal degradation product of CBD. The relative amount of cannabinol was significantly higher in oxidative conditions at each studied temperature, indicating the effect of oxygen in the reaction mechanism. In addition to the driving force of the aromatization in both atmospheres,

dehydrogenation by oxygen with water elimination may play additional role in oxidative atmosphere. The most intense cannabinol formation (10.4%) was observed at 400 °C in oxidative atmosphere.

Cannabichromene also formed through cyclization reaction. However, one of the phenolic O of the CBD molecule attacked the double bond of the cyclohexene ring at C substituted with methyl group in this case, while the cyclohexene ring opened up by C–C scission to form the chromene frame. Formation of cannabichromene was more pronounced in inert atmosphere compared to the oxidative condition at 250 °C. At higher temperatures there was no significant difference and the relative yield of cannabichromene was decreased.

Cannabielsoin was only detected under oxidative conditions. In this transformation, one of the phenolic O of CBD linked similarly to the double bond of its cyclohexene ring, but at the secondary carbon, while a hydroxyl group formed at the adjacent C substituted with methyl group via the oxidative medium. The relative intensity of cannabielsoin was around 3%, and its quantity was not much affected in the temperature range of 250–500 °C.

At higher temperatures, the share of the decomposition products formed through cyclization reaction was decreased, while the relative intensity of smaller molecules formed by C–C bond scission increased in the pyrolyzate. These identified products were formed by the scission of the bond connecting the pentylbenzenediol and the *p*-mentha-1,8-dienyl moieties of the CBD molecule. Menthatriene isomers appeared at 250 °C in oxidative atmosphere, while in inert atmosphere only above 400 °C, indicating that the presence of oxygen promoted the cleavage of the molecule. The relative amount of menthatrienes were the highest at 500 °C in both inert and oxidative atmospheres.

## Discussion

Here we present the first extensive analysis of the pyrolysis of CBD under conditions relevant in case of using the substance in e-cigarettes. THC was the main pyrolysis product at all temperatures under both oxidative and inert conditions. The typical THC content (the integer number closest to the median values) of joints used for recreational purposes is around 7 mg<sup>18</sup>. A Swiss analysis based on 20 samples found that the total CBD content of e-liquids ranged between 0.182 and 3.346% and differed in half of the samples from the claimed content<sup>19</sup>. According to a study, two e-liquids were labeled to contain 3.3 mg/mL of CBD, however they were found to contain 6.5 and 7.6 mg/mL of CBD<sup>20</sup>. On the basis of our results, it might be assumed that up to 0.5–1 mg of THC may be intaken by vaping each mL of CBD-containing e-liquid. However, it should be mentioned that the applied experimental method revealed the thermal degradation of pure CBD. Therefore, the possible effect of the vaping fluid (e.g. PG/VG<sup>20</sup>) on the stability and breakdown pattern was not taken into consideration. Nevertheless, due to the observed high conversion rate of CBD to THC, the results highly draw attention on the risk of CBD-containing e-liquids. The heating time in an e-cigarette may vary depending on its type and customer habit. Despite the relatively long isothermal period (5 min) applied in the pyrolysis method, a short residence time in the hot zone of the pyrolyzer is expected, because the boiling point of CBD and its degradation products is relatively low (155–185 °C) and high flow rate (276 mL/min) was applied during pyrolysis.

Recently, the incidence of the so-called vaping-associated pulmonary illness (VAPI) has been increasing (this condition is also known as EVALI, e-cigarette or vaping product use-

associated lung injury). Until February 2020, more than 2800 patients had been hospitalized in the US due to VAPI, with a total of 68 deaths reported <sup>21</sup>. Although the etiology of VAPI has not been elucidated yet, nicotine, THC, CBD, and vitamin E are among the most suspected ingredients with a link to the pathogenesis of the disease <sup>22</sup>.

The presence of CBD in e-cigarettes might pose dual risk. First, as a precursor of the psychoactive THC, it bears all the dangers related to THC use. Consumers of CBD-containing e-cigarettes may also be involuntarily exposed to the psychoactive THC. Moreover, its use in e-cigarette liquids is not regulated; therefore, the exposure of e-cigarette users to THC is unknown. And second, CBD itself is a pharmacologically active compound with remarkable activities on the central nervous and the cardiovascular system and is marketed as prescription-only medicine with several potential adverse effects such as somnolence, decreased appetite, diarrhea, pyrexia, fatigue, and vomiting<sup>23</sup>.

The results presented here might be important contributions to the legal discretion of CBD. Although according to the French law, the distribution of CBD-containing e-cigarette cartridges was considered as infringements of the legislation on poisonous substances, the Court of Justice of the European Union had a different interpretation<sup>24</sup>. Albeit CBD itself is void of psychoactivity, our results underline, that remarkable amount of THC might be formed from CBD during evaporation in an e-cigarette. Therefore, the standpoint, that CBD does not appear to have any psychotropic effect or any harmful effect on human health on the basis of available scientific data, should be reconsidered. From a scientific point of view, when used in an e-cigarette, CBD is the precursor of THC, although this fact is not reflected yet in drug policy and legislation.

## Methods

A 1 mg/mL CBD in methanol solution was purchased from Supelco (certified reference material, Cerilliant), and kept at – 20 °C till the analysis. The experiments were performed either in a gas mixture of 9.34% (*n/n*) oxygen and 90.66% (*n/n*) nitrogen or in helium atmosphere.

The experimental method to simulate the low-temperature tobacco heating conditions was developed in our earlier study<sup>12</sup>. This method was adopted and modified by using various temperatures<sup>11</sup> to study the breakdown pattern of CBD; therefore, the experimental conditions are described here briefly.

Py-GC/MS analyses have been carried out using a Pyroprobe 2000 (CDS Analytical, Oxford, PA, USA) pyrolyzer equipped with a platinum heating coil and a quartz sample tube. A total 15  $\mu$ L aliquot of solution was dispensed in 5  $\mu$ L portions onto a piece of quartz wool placed in the quartz tube and it was rested for 3 min at room temperature to allow evaporating the majority of the solvent after each portion. The quartz tube was placed in the Pyroprobe, at room temperature, which was then inserted into the pre-heated pyrolysis chamber. The temperature of the pyrolysis chamber was 280 °C, except in case of pyrolysis experiments performed at 250 °C, when the chamber temperature was set at 250 °C as well. The pyrolysis chamber was flushed at a 276 mL/min flow rate by the applied gas mixture. The sample was then heated at a maximal heating rate (set at 999 °C/s) to the final pyrolysis temperature. The experiments were performed at five different pyrolysis temperatures in a temperature range of 250–500 °C, using 5 min isotherm period in the case of each pyrolysis temperature. Oxidative experiments were performed in a gas mixture of 9% oxygen and 91% nitrogen. In

order to reveal the role of oxygen in the thermal degradation reactions, additional experiments were performed in helium atmosphere, applying the same pyrolysis temperatures. The volatile products were purged on-line to a DB-1701 capillary column (30 m × 0.25 mm i.d., 0.25 μm film thickness) of the GC/MS (Agilent 6890 GC/5973 MSD) system. At the end of the pyrolysis, the pyrolysis gas flow was closed, and helium carrier gas was supplied to the GC/MS. Solvent delay of 7 min was applied to protect the MS. The GC oven was programmed to 7 min isotherm period at 40 °C before increase to 280 °C at a rate of 10 °C/min. The range of *m/z* 29–400 was scanned by the mass spectrometer in EI mode (70 eV). At least three parallel experiments were performed at each temperature. The identification of the pyrolysis products (see Supplementary Table S1) was based on the combined Wiley Registry 9th edition/NIST 2011 mass spectral library and literature data<sup>25,26,27,28,29</sup>. The percentages of the compounds were estimated using the peak areas of the total ion current chromatograms.

## References

1. 1.Gülck, T. & Møller, B. L. Phytocannabinoids: Origins and biosynthesis. *Trends Plant Sci.* **25**, 985–1004. <https://doi.org/10.1016/j.tplants.2020.05.005> (2020).  
[CAS](#) [Article](#) [PubMed](#) [Google Scholar](#)
2. 2.HerbalGram: US Sales of Herbal Supplements Increase by 8.6% in 2019. <http://cms.herbalgram.org/herbalgram/issue127/hg127-mktrpt-2019.html?ts=1606734640&signature=e495142878bc6459b623529f1139cfe3>. Accessed 30 Nov 2020.
3. 3.Pisanti, S. & Bifulco, M. Medical Cannabis: A plurimillennial history of an evergreen. *J. Cell. Physiol.* **234**, 8342–8351. <https://doi.org/10.1002/jcp.27725> (2019).  
[CAS](#) [Article](#) [PubMed](#) [Google Scholar](#)
4. 4.Smart, R. *et al.* Variation in cannabis potency and prices in a newly legal market: Evidence from 30 million cannabis sales in Washington state. *Addiction* **112**, 2167–2177. <https://doi.org/10.1111/add.13886> (2017).  
[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)
5. 5.Chen, J. *et al.* All up in smoke: Vaping-associated lung injury. *J. Community Hosp. Intern. Med. Perspect.* **10**, 571–578. <https://doi.org/10.1080/20009666.2020.1800978> (2020).  
[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)
6. 6.Orvos, P. *et al.* The electrophysiological effect of cannabidiol on hERG current and in guinea-pig and rabbit cardiac preparations. *Sci. Rep.* <https://doi.org/10.1038/s41598-020-73165-2> (2020).  
[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)
7. 7.Court of Justice of the European Union. A Member State may not prohibit the marketing of cannabidiol (CBD) lawfully produced in another Member State when it is extracted from the *Cannabis sativa* plant in its entirety and not solely from its fibres

and seeds. *Press Release No 141/20 2020 20–21* (2009).

8. 8.Mikeš, F. & Waser, P. G. Marihuana components: Effects of smoking on  $\Delta^9$ -tetrahydrocannabinol and cannabidiol. *Science (80-)* **172**, 1158–1159. <https://doi.org/10.1126/science.172.3988.1158> (1971).  
[ADS](#) [Article](#) [Google Scholar](#)
9. 9.Küppers, F. J. E. M. *et al.* Cannabis-VIII. Pyrolysis of cannabidiol. Structure elucidation of the main pyrolytic product. *Tetrahedron* **29**, 2797–2802. [https://doi.org/10.1016/S0040-4020\(01\)93404-0](https://doi.org/10.1016/S0040-4020(01)93404-0) (1973).  
[Article](#) [Google Scholar](#)
10. 10.Tjeerdema, R. S. The pyrolysis of cannabinoids. *Rev. Environ. Contam. Toxicol.* **99**, 61–81 (1987).  
[CAS](#) [PubMed](#) [Google Scholar](#)
11. 11.Chen, W. *et al.* Measurement of heating coil temperature for e-cigarettes with a “top-coil” clearomizer. *PLoS ONE* **13**, 1–16. <https://doi.org/10.1371/journal.pone.0195925> (2018).  
[CAS](#) [Article](#) [Google Scholar](#)
12. 12.Czégény, Z. *et al.* Thermal behaviour of selected flavour ingredients and additives under simulated cigarette combustion and tobacco heating conditions. *J. Anal. Appl. Pyrolysis* **121**, 190–204. <https://doi.org/10.1016/j.jaap.2016.07.020> (2016).  
[CAS](#) [Article](#) [Google Scholar](#)
13. 13.Dibaji, S. A. R. *et al.* Accuracy of commercial electronic nicotine delivery systems (ENDS) temperature control technology. *PLoS ONE* **13**, e0206937. <https://doi.org/10.1371/journal.pone.0206937> (2018).  
[CAS](#) [Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)
14. 14Wagner, J., Chen, W. & Vrdoljak, G. Vaping cartridge heating element compositions and evidence of high temperatures. *PLoS ONE* <https://doi.org/10.1371/journal.pone.0240613> (2020).  
[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)
15. 15.Blazsó, M. *et al.* Thermo-oxidative degradation of aromatic flavour compounds under simulated tobacco heating product condition. *J. Anal. Appl. Pyrolysis* **134**, 405–414. <https://doi.org/10.1016/j.jaap.2018.07.007> (2018).  
[CAS](#) [Article](#) [Google Scholar](#)
16. 16.Grafström, K. *et al.* Effects of long term storage on secondary metabolite profiles of cannabis resin. *Forensic Sci. Int.* **301**, 331–340. <https://doi.org/10.1016/j.forsciint.2019.05.035> (2019).  
[CAS](#) [Article](#) [PubMed](#) [Google Scholar](#)
17. 17.WHO Expert Committee on Drug Dependence, fortieth report. Geneva: World Health Organization. (WHO Technical Report Series, No. 1013).. Licence: CC BY-NC-SA 3.0 IGO (2018).

18. 18.CasajuaanaKögel, C. *et al.* The standard joint unit. *Drug Alcohol Depend.* **176**, 109–116. <https://doi.org/10.1016/j.drugalcdep.2017.03.010> (2017).  
[Article](#) [Google Scholar](#)
19. 19.Grafinger, K. E. *et al.* Cannabidiol and tetrahydrocannabinol concentrations in commercially available CBD E-liquids in Switzerland. *Forensic Sci. Int.* **310**, 110261. <https://doi.org/10.1016/j.forsciint.2020.110261> (2020).  
[CAS](#) [Article](#) [PubMed](#) [Google Scholar](#)
20. 20.Peace, M. R. *et al.* Evaluation of two commercially available cannabidiol formulations for use in electronic cigarettes. *Front. Pharmacol.* **7**, 279. <https://doi.org/10.3389/fphar.2016.00279> (2016).  
[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)
21. 21.Zulfiqar, H. & Rahman, O. *Vaping Associated Pulmonary Injury*. StatPearls Publishing 2020. <http://www.ncbi.nlm.nih.gov/pubmed/32809491>. Accessed 7 Dec 2020.
22. 22.Hage, R., Fretz, V. & Schuurmans, M. M. Electronic cigarettes and vaping associated pulmonary illness (VAPI): A narrative review. *Pulmonology.* **26**, 291–303. <https://doi.org/10.1016/j.pulmoe.2020.02.009> (2020).  
[CAS](#) [Article](#) [PubMed](#) [Google Scholar](#)
23. 23.European Medicines Agency. Epidyolex. <https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex>. Accessed 06 Jan 2021
24. 24.Judgement of the Court (Reference for a preliminary ruling—Free movement of goods—Common organisation of the markets in the flax and hemp sector—Exceptions—Protection of public health—National legislation limiting the industrialisation and market. <http://curia.europa.eu/juris/document/document.jsf?docid=233925&mode=req&pageIndex=1&dir=&occ=first&part=1&text=&doclang=EN&cid=17576455>. Accessed 8 Dec 2020.
25. 25.Luteyn, J. M., Spronck, H. J. W. & Salemink, C. A. Cannabis XVIII: Isolation and synthesis of olivetol derivatives formed in the pyrolysis of cannabidiol. *Recl des TravChim des Pays-Bas* **97**, 187–190. <https://doi.org/10.1002/recl.19780970704> (1978).  
[CAS](#) [Article](#) [Google Scholar](#)
26. 26.Srebnik, M. *et al.* Base-catalysed double-bond isomerizations of cannabinoids: Structural and stereochemical aspects. *J. Chem. Soc. Perkin. Trans.* **1**, 2881–2886. <https://doi.org/10.1039/p19840002881> (1984).  
[Article](#) [Google Scholar](#)
27. 27Pronck, H. J. W. & Lousberg, R. J. J. C. Pyrolysis of cannabidiol. Structure elucidation of a major pyrolytic conversion product. *Experientia* **33**, 705–706. <https://doi.org/10.1007/BF01944139> (1977).

[Article](#) [Google Scholar](#)

28. 28.Hazekamp, A. *et al.* Chromatographic and spectroscopic data of cannabinoids from *Cannabis sativa* L.. *J. Liq. Chromatogr. Relat. Technol.* **28**, 2361–2382. <https://doi.org/10.1080/10826070500187558> (2005).  
[CAS](#) [Article](#) [Google Scholar](#)
29. 29.Küppers, F. J. E. M. *et al.* Cannabis. XIV. Pyrolysis of cannabidiol-analysis of the volatile constituents. *J. Chromatogr. A* **108**, 375–379. [https://doi.org/10.1016/S0021-9673\(00\)84684-1](https://doi.org/10.1016/S0021-9673(00)84684-1) (1975).  
[Article](#) [Google Scholar](#)

[Download references](#)

## Acknowledgements

Financial support from the Economic Development and Innovation Operative Program GINOP-2.3.2-15-2016-00012 is gratefully acknowledged.

## Author information

### Affiliations

1. Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Eötvös Loránd Research Network, Magyar tudósok körútja 2, Budapest, 1117, Hungary  
Zsuzsanna Czégény, Gréta Nagy, Bence Babinszki & Zoltán Sebestyén
2. Department of Pharmacognosy, Faculty of Pharmacy, University of Szeged, Eötvös u. 6, Szeged, 6720, Hungary  
Ákos Bajtel, Tivadar Kiss, Barbara Tóth & Dezső Csupor
3. Institute for Translational Medicine, Medical School, University of Pécs, Szigeti út 12, Pécs, 7624, Hungary  
Boglárka Csupor-Löffler & Dezső Csupor

### Authors

1. Zsuzsanna Czégény You can also search for this author in [PubMed](#) [Google Scholar](#)
2. Gréta Nagy You can also search for this author in [PubMed](#) [Google Scholar](#)

3. Bence Babinszki You can also search for this author in [PubMed Google Scholar](#)
4. Ákos Bajtel You can also search for this author in [PubMed Google Scholar](#)
5. Zoltán Sebestyén You can also search for this author in [PubMed Google Scholar](#)
6. Tivadar Kiss You can also search for this author in [PubMed Google Scholar](#)
7. Boglárka Csupor-Löffler You can also search for this author in [PubMed Google Scholar](#)
8. Barbara Tóth You can also search for this author in [PubMed Google Scholar](#)
9. Dezső Csupor You can also search for this author in [PubMed Google Scholar](#)

## **Contributions**

D.C. conceptualized, Z.C. designed the study. G.N. and B.B. performed the experiments, B.B. established the methodology, G.N. collected the data, Z.C., B.B. and G.N. did the data analyses, Z.C. with B.B. and Z.S. interpreted the data. T.K., B.T., B.C.L., Z.C. and B.B. did the literature search. D.C. and Z.C. led the writing of the first draft of the manuscript, Á.B., B.C.L. and T.K. were involved in subsequent drafts; G.N., B.B. and Z.S. took part in writing review and editing. D.C. and Z.C. are guarantors for this paper and were the supervisors of this project. All authors read and approved the final manuscript.

## **Corresponding author**

Correspondence to [Dezső Csupor](#).

## **Ethics declarations**

### **Competing interests**

The authors declare no competing interests.

## **Additional information**

### **Publisher's note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

# Supplementary Information

## Rights and permissions

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

[Reprints and Permissions](#)

## About this article

### Cite this article

Czégény, Z., Nagy, G., Babinszki, B. *et al.* CBD, a precursor of THC in e-cigarettes. *Sci Rep* **11**, 8951 (2021). <https://doi.org/10.1038/s41598-021-88389-z>

[Download citation](#)

- Received: 12 February 2021
- Accepted: 06 April 2021
- Published: 26 April 2021
- DOI: <https://doi.org/10.1038/s41598-021-88389-z>

### Subjects

## Comments

By submitting a comment you agree to abide by our [Terms](#) and [Community Guidelines](#). If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

